ECO Animal Health Group (EAH)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 74.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 131.50
  • 52 Week Low: 63.00
  • Currency: UK Pounds
  • Shares Issued: 67.76m
  • Volume: 34,833
  • Market Cap: £50.14m

Eco Animal Health enters two pig vaccine partnerships

By Josh White

Date: Thursday 15 Oct 2020

LONDON (ShareCast) - (Sharecast News) - Eco Animal Health has entered into two worldwide exclusive research partnerships, it announced on Thursday, to develop novel vaccines for use in pigs.
The AIM-traded firm said the two new partnerships with the Pirbright Institute in the UK and the Vaccine Group (TVG) reinforced its commitment to research and development focussed on diseases of economic importance in pigs and poultry.

It said the first collaboration would, over an 18 month period, use technologies at Pirbright to develop killed PRRSV vaccine candidates capable of entering a full development programme, and providing immunity against multiple strains of the virus.

A killed PRRSV vaccine would offer an "attractive alternative" to the current generation of live vaccines, the board said, which were only partially effective against different strains and suffered from safety constraints owing to the potential for the live vaccine virus to revert back to an infectious form.

The second collaboration would test vaccine candidates at Pirbright, created using TVG technology, to insert non-infectious PRRSV genes supplied by Pirbright into a benign herpesvirus, which would then stimulate the immune system when delivered into animals.

Vaccines that use herpesviruses as their base have been shown to provoke "particularly strong" reactions from T-cells, which are a vital part of the antiviral response.

The company said it expected that the initial phase, to develop candidate vaccines capable of entering a full development programme, would be up to 18 months.

It said the two PRRSV species, being type-1 and type-2, were responsible for one of the most economically damaging diseases to the global pig industry, costing European pig farmers an estimated €1.5bn a year, and those in the US around $600m.

"We are delighted to have partnered with The Pirbright Institute once again to develop novel vaccines, enabling the protection of pigs whilst reducing the risks associated with the use of live vaccines for a disease of global economic importance," said chief executive officer Marc Loomes.

"Our collaboration with the Pirbright Institute and TVG leverages the deep scientific expertise of the Pirbright Institute and TVG's novel herpesvirus vector technology in an exciting new approach to PRRSV vaccination."

At 1006 BST, shares in Eco Animal Health were up 1.13% at 205.8p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

EAH Market Data

Currency UK Pounds
Share Price 74.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 131.50
52 Week Low 63.00
Volume 34,833
Shares Issued 67.76m
Market Cap £50.14m

EAH Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
61.51% below the market average61.51% below the market average61.51% below the market average61.51% below the market average61.51% below the market average
68% below the sector average68% below the sector average68% below the sector average68% below the sector average68% below the sector average
Price Trend
64.89% below the market average64.89% below the market average64.89% below the market average64.89% below the market average64.89% below the market average
24% below the sector average24% below the sector average24% below the sector average24% below the sector average24% below the sector average
Income Not Available
Growth
34.04% below the market average34.04% below the market average34.04% below the market average34.04% below the market average34.04% below the market average
41.18% below the sector average41.18% below the sector average41.18% below the sector average41.18% below the sector average41.18% below the sector average

What The Brokers Say

Strong Buy 1
Buy 2
Neutral 0
Sell 0
Strong Sell 0
Total 3
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

EAH Dividends

  Latest Previous
  Final Final
Ex-Div 23-Sep-21 26-Sep-19
Paid 22-Oct-21 16-Oct-19
Amount 1.00p 7.04p

Trades for 31-Oct-2024

Time Volume / Share Price
16:03 129 @ 74.00p
16:01 85 @ 74.00p
11:28 20,000 @ 73.68p
09:02 337 @ 74.00p
08:56 7,512 @ 72.00p

EAH Key Personnel

CFO Christopher Wilks
CEO David Hallas

Top of Page